This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $661.32 in the latest trading session, marking a +0.86% move from the prior day.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.
Idexx Laboratories (IDXX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $596.35, moving -1.49% from the previous trading session.
Idexx Laboratories (IDXX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $618.55 in the latest trading session, marking a +1.16% move from the prior day.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.
Idexx (IDXX) Down 4.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Top Stock Reports for Walmart, Honeywell & Zoetis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS).
IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints
by Zacks Equity Research
IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
Top Research Reports for Mastercard, Linde & Lam Research
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Linde plc (LIN), and Lam Research Corporation (LRCX).
IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.98% and 2.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Idexx Laboratories (IDXX) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
If You Invested $1000 in Idexx Laboratories 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.